Active Ingredient(s): Idelalisib
FDA Approved: * July 23, 2014
Category: Cancer

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".

Zydelig Overview

Idelalisib, sold under the brand name Zydelig, is a medication used to treat certain blood cancers.[2][1] The substance acts as a phosphoinositide 3-kinase inhibitor; more specifically, it blocks P110δ, the delta isoform of the enzyme phosphoinositide 3-kinase.[4][5] It was developed by Gilead Sciences. Idelalisib had annual sales of $168 million (USD) during the year of 2016, up from $132 million (USD) in 2015.[6&a...

Read more Zydelig Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Idelalisib

Recent Zydelig Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

  • Tablet: 100mg, 150mg
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Zydelig: (2 results)

Sorted by National Drug Code
  • 61958-1701 Zydelig 100 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.
  • 61958-1702 Zydelig 150 mg Oral Tablet, Film Coated by Gilead Sciences, Inc.

Other drugs which contain Idelalisib or a similar ingredient: (1 result)